Litigation Details for ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
✉ Email this page to a colleague
ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-01-08 |
Court | District Court, D. New Jersey | Date Terminated | 2021-02-28 |
Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
Jury Demand | None | Referred To | Douglas Arpert |
Patents | 9,161,926; 9,517,219 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC.
Details for ALMIRALL, LLC v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2020-01-08 | 1 | Complaint | dapsone) gel, 7.5%; ANDA No. 214019; U.S. Patent Nos. 9,161,926 and 8,517,219” (the “Notice Letter”). …This is an action for patent infringement brought under the United States Patent Act and the Hatch-Waxman…the expiration of United States Patent No. 9,517,219 (“the ’219 patent”), which covers, inter alia, the… THE PATENT-IN-SUIT 25. On December 13, 2016, the United States Patent and Trademark… the claims of the ’219 patent. 41. The claims of the ʼ219 patent are not invalid. | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |